JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS *J Label Compd Radiopharm* 2003; **46**: 231–242. Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/jlcr.662

Research Article

A new synthesis of $[26,28^{-2}H_6]$ brassinolide and $[26,28^{-2}H_6]$ castasterone via an unusual methyl migration

A. Kolbe, A. Porzel, J. Schmidt and G. Adam* Institut für Pflanzenbiochemie, Weinberg 3, D 06120 Halle/Saale, Germany

Dedicated to Professor Dr Peter Welzel on the occasion of his 65th birthday

Summary

Deuterium-labelled brassinosteroids, namely $[26, 28^{-2}H_6]$ castasterone, **8**, and $[26, 28^{-2}H_6]$ brassinolide, **9**, were synthesized starting from 6, 6ethylenedioxy-20-formyl-2 α , 3 α -isopropylidenedioxy-5 α -pregnane, **1**, and $3^{-1}H_3$]methyl-but-1-yne-[4, 4, 4^{-2}H_3], **11**. Upon alkylating cleavage of the epoxide **6** with trimethylaluminium-*n*-butyllithium an unusual migration of a neighbouring $[^2H_3]$ methyl group takes place to afford deuteriation at positions 26 and 28. Copyright © 2002 John Wiley & Sons, Ltd.

Key Words: brassinosteroids; $[26, 28^{-2}H_6]$ castasterone; $[26, 28^{-2}H_6]$ brassinolide; $3-[^2H_3]$ methyl-but-1-yne- $[4, 4, 4^{-2}H_3]$

Introduction

The brassinosteroids are steroidal phytohormones of ubiquitous occurrence in the plant kingdom showing high growth promoting and antistress activity. Up until now more than 40 native brassinosteroids have been isolated and characterized from a large variety of plants.¹⁻³ For biosynthetic and metabolic studies⁴ of brassinosteroids in plants deuterium-labelled versions^{5, 6} are needed. Thus, Takatsuto and Ikekawa⁷ synthesized a series of [26, 28-²H₆]brassinosteroids starting

*Correspondence to: G. Adam, Leibniz Institute of Plant Biochemistry, Weinberg 3, D-06120 Halle/Saale, Germany. E-mail: gadam@ipb-halle.de

Copyright © 2002 John Wiley & Sons, Ltd.




Figure 1. Syntheses of [26, 28-²H₆]castasterone, 8, and [26, 28-²H₆]brassinolide, 9

from a 3,5-cyclo-22-aldehyde and $[26, 28^{-2}H_6]$ crinosterol, respectively, by stepwise introduction of the label. More recently, the synthesis of $[25, 26, 27^{-2}H_7]$ brassinolide from the parent brassinolide has been published.⁸ In this paper we describe a new synthesis of $[26, 28^{-2}H_6]$ castasterone, **8**, and $[26, 28^{-2}H_6]$ brassinolide, **9**, via side-chain construction starting from 6, 6-ethylenedioxy-20-formyl-2 α , 3 α -isopropylidenedioxy-5 α -pregnane, **1**, and 3- $[^{2}H_{3}]$ methyl-but-1-yne- $[4, 4, 4^{-2}H_{3}]$, **11**, involving an unusual methyl migration (Figure 1).

Copyright © 2002 John Wiley & Sons, Ltd.

J Label Compd Radiopharm 2003; 46: 231-242

Results and discussion

The side-chain unit $3-[^{2}H_{3}]$ methyl-but-1-yne-[4, 4, 4- $^{2}H_{3}]$, 9 11, was synthesized in three steps starting from sodium acetylide and [²H₆]acetone in a similar manner to that described for the unlabelled compound.^{10, 11, 12} Because acetylene in the steel flask is acetone, the isotopic incorporation dissolved in of the $3-[^{2}H_{3}]$ methyl-but-1-yne-[4, 4, $4-^{2}H_{3}]$ was somewhat reduced (88%). The lithium salt of this deuteriated side-chain synthon was coupled with the protected steroidal 22-aldehyde 1^{12} which had been produced in eight steps starting from stigmasterol. The obtained diastereomeric mixture of the acetylenic 22-alcohols 2 were oxidized by pyridinium chlorochromate to give the acetylenic 22-ketosteroid **3**. Subsequent reduction with R-Alpine-borane ((+)- α -pinene) as a chiral reagent¹³ led stereoselectively to the desired 22R alcohol 4. Partial hydrogenation of 4 over P-2 nickel catalyst in the presence of ethylenediamine afforded the allylic 22-alcohol 5. Subsequent epoxidation of the allyl alcohol with *m*-chloroperbenzoic acid in the presence of sodium hydrogen phosphate gave the 23,24 epoxide **6**.^{12,14}

For the alkylating fission of the epoxy ring¹⁵ compound 6 was dissolved in a mixture of *n*-hexane and cyclohexane (7.5:2) and cooled to -78° C under an argon atmosphere. To the stirred solution trimethylaluminium (2 M in *n*-heptane) and *n*-butyllithium (1.6 M in *n*-hexane) were added to give, after SiO₂-chromatography, 48% of the 22R, 23R-diol 7. As discussed below the NMR data of this castasterone derivative 7 indicated deuteriation at the C-26 and C-28 positions instead of that the expected C-26 and C-27 positions. Thus, during the cleavage of the epoxy ring migration of one [²H₃]methyl group from position 25 to 24 must have taken place probably via an intermediate 6a. Removal of the protective groups with 80% acetic acid afforded the desired labelled castasterone. 8.

Some of 8 was purified over HPLC whereas a second part was transformed directly via Baeyer-Villiger oxidation with peroxytrifluoroacetic acid to afford $[26, 28^{-2}H_6]$ brassinolide, 9, and the isomeric 5a-oxa, 6-oxo-lactone 10 in a 6:1 ratio. Additionally in this procedure, small amounts of a monotrifluoroacetic acid ester of [26, 28-²H₆]brassinolide were obtained indicating side-chain esterification at C-22 or C-23. Pure [26, 28-²H₆]brassinolide, 9, was obtained

Position	Compound number					
	9	8	6	6	8	6
	$\delta_{1\mathrm{H}}lpha/eta$	$\delta_{ m IH} lpha / eta$	$\delta_{1\mathrm{H}}lpha/eta$	δ_{13C}	δ_{13C}	δ_{13C}
	1.06/1.91	1.56/1.67	1.53/1.852 dd	42.8	41.0	41.0
	4.098 m	3.656 ddd	3.631 ddd	73.0	69.1	67.7
		(11.9/4.9/3.1)	(12.1/4.5/2.7)			
	4.273 m	3.945 m	3.958 br s	72.9	69.5	67.7
	$2.15^{a}/1.79^{a}$	1.756 ddd (15.0/3.6/3.6)/1.66	1.901 ddd (15.3/4.3/ 4.3)/2.097 ddd (15.3/12.2/2.3)	22.1	27.8	30.9
	1.81	2.725 dd (12.4/3.3)	3.136 dd (12.2/4.4)	45.6	52.1	40.8
				109.6	215.1	177.
	1.03/1.752 dd (13.2/3.7)	2.108 dd (13.3/12.1)/2.205	4.10/4.10	41.1	47.5	70.4
		dd(13.3/4.9)				
	1.51	1.80	1.72	33.0	39.2	38.9
	0.783 ddd (12 1/11 1/4 2)	1.43	1.28	52.9	55.1	57.9
0			I	38.1	43.6	38.(
	1.55/1.30	1.69/1.40	1.78/1.39	20.9	22.4	22.(
12	1.21/1.977 ddd (12.3/3.3/2.8)	1.31/2.06	1.24/1.98	39.7	40.9	39.4
3				42.4	43.9	42.2
14	1.11	1.38	1.20	55.8	57.9	51.1
S	1.59/1.07	1.59/1.13	1.68/1.24	24.2	24.8	24.5
		-	_			

234

A. KOLBE ET AL.

52.0 11.5 15.2 36.7	11.6	73.0 39.7[40.0]	30.1[30.4] 20.5[20.6] proR	19.7[20.5] proS 9.2[9.9]	
53.7 12.3 13.8 38.5	12.5 75.7	74.4 41.6	31.4 21.3	[31.1 ^b] [10.7 ^b]	
52.1 12.0 13.5 40.3	12.7 70.5	60.1 63.3	26.6 [20.3]	[18.8] 28.7 26.7 107.5 65.5	04.2
1.56 0.720 s 0.912 s 1.47	0.888 d (6.7) 3.509 dd (8.5/1.5)	3.687 dd (8.5/1.9) 1.15	1.60 0.958 d (6.7) [0.963 d (6.7)] pro R	-[0.943 d (6.7)] proS -[0.839 d (6.9)]	
1.61 0.724 s 0.762 s 1.50	0.908 d (6.7) 3.510 dd (8.3/1.3)	3.676 dd (8.3/2.0) 1.14	1.61 0.959 d (6.7) [0.964 d (6.7)]	– [0.933 d (6.8)] ProS – [0.838 d (6.9)]	
1.55 0.677 s 0.837 s 1.53	1.059 d (6.3) 3.603 brdd (6.4/4.3)	3.059 dd (6.4/4.3) (6.4/4.3) 2.669 dd	(9.7/4.3) 1.54 - [1.09 ^a]	$ \begin{array}{c} - \left[0.974 \text{ d} \\ (6.7^{4}) \right] \\ (6.7^{4}) \\ - \\ 1.479 \text{ s} \\ 1.327 \text{ s} \\ 3.95/3.91 \\ 2.010 \\ 2.01$	
Conversion		2 2 2 42	50 22 50 32 20 42	27 27 28 28 28 20 20 20 20 20 20 20 20 20 20 20 20 20	

235

Copyright © 2002 John Wiley & Sons, Ltd. J Label Compd Radiopharm 2003; 46: 231-242

by HPLC separation. The deuterium incorporation of the labelled castasterone and brassinolide at the specified sites was found to be 86.6%.

¹H and ¹³C NMR chemical shifts of $(22R, 23S, 24R)-2\alpha$, 3α -isopropylidenedioxy-6, 6-ethylendioxy-22-hydroxy-23, 24epoxy- 5α -cholestane $[26,27-^{2}H_{6}]$, **6**, $[26, 28-^{2}H_{6}]$ castasterone, **8**, and $[26, 28-^{2}H_{6}]$ brassinolide, **9**, (Table 1) were unambiguously assigned, based on one- and twodimensional experiments, including homo- and heteronulear shift correlation spectra.

The positions of the deuteriated methyl groups of castasterone were verified by detailed investigation. The high-field region of the proton spectrum showed, besides the two singlets of Me-18 (δ 0.724) and Me-19 (δ 0.762), two intense doublets at δ 0.908 (J = 6.7 Hz) and $\delta 0.959$ (J = 6.7 Hz) and three weak doublets $(\delta 0.964, J = 6.7 \text{ Hz}; 0.933, J = 6.8 \text{ and } \delta 0.838, J = 6.9 \text{ Hz}).$ The signal at δ 0.908 showed HMBC correlations with C-17 (δ 53.7), C-20 (δ 38.5) and C-22 (δ 75.7). A correlation with the ¹³C signal at δ 53.7 was also found for Me-18 (δ 0.724) and therefore this carbon signal was assigned to C-17 and the doublet at δ 0.908 to Me-21. The ¹H signal at δ 0.838 had a relative intensity of about 15% compared with the signal of Me-21 and showed HMBC correlations with C-23 (\$ 74.4), C-24 (\$ 41.6) and C-25 (\$ 31.4). Consequently, it had to be assigned to Me-28 in the non-deuteriated portion of castasterone. This finding verified unequivocally the migration of one [²H₃]methyl group from C-25 to C-24 during the methylation step 6 to 7. The 2 weak doublets at δ 0.964 and δ 0.933 were assigned to Me-26^{proR} and Me-27^{proS}, respectively, in the undeuteriated portion of the NMR spectrum of castasterone.¹⁶ The intense doublet at δ 0.959 was assigned to Me-26^{proR} of the main compound by its HMBC correlations with C-24 (δ 41.6) and C-25 (δ 31.4). No correlation with C-27^{proS} could be detected in the routine HMBC spectrum. However, an HMBC experiment with deuterium decoupling showed the cross peak between H₃-26 and C-27. In the ${}^{13}C{}^{1}H{}$ spectrum the fully deuteriated carbons C-27^{proS} and C-28 displayed weak multiplets at δ 19.9 and δ 9.5, respectively. In each case the upfield shift of 1.2 ppm by comparison with the corresponding signals of the undeuteriated spectrum is due to the deuterium isotope effect, which is known to be about 0.4 ppm per deuterium atom in an α position.¹⁷

Conclusions

[26, 28-²H₆]Castasterone, **8**, and [26, 28-²H₆]brassinolide, **9**, were synthesized starting from 6, 6-ethylenedioxy-20-formyl-2 α , 3 α -isopropylidenedioxy-5 α -pregnane, **1**, and 3-[²H₃]methyl-but-1-yne-[4, 4, 4-²H₃], **11**. In the alkylating opening of the epoxy ring in **6** with trimethylaluminium a migration of one [²H₃]methyl group from positions 25 to 24 takes place, leading to the corresponding 26,28-deuteriated compound **7** instead of the initially expected [26, 27-²H₆] labelled brassinosteroids. It can also be assumed that during the corresponding synthesis of unlabelled brassinosteroids¹² such a positional change of one methyl-group takes place.

Experimental

Materials and methods

For column chromatography we used Merck silica gel 60 (particle size 0.040–0.063 mm, 230–400 mesh ASTM). Melting points (uncorrected) were determined on a Boetius heating table. Optical rotations $[\alpha]_D$ were measured at room temperature on a Jasco Digital Polarimeter DIP-1000.

EIMS (DIS): 70 eV, AMD 402 (AMD Intectra.) GCMS: MD-800 (Fisons Instruments), EI 70 eV; source temperature 200°C; column DB-5MS (J&W, 15 m \times 0.32 mm, 0.25 µm film thickness), injection temp. 260°C, interface temp. 300°C, carrier gas He, flow rate 1.3 ml/min. splitless injection, column temperature program: 170°C for 1 min, then raised to 290°C at a rate of 30 grd/min and held on this temperature for 20 min; positive ion ESI mass spectra

NMR: 1D: VARIAN GEMINI spectrometer 300, 300.24 MHz and 75.5 MHz, solvent CD₃OD and CDCl₃, 2D: ($^{1}H-^{1}H-COSY$, GHSQC and GHMBC) NMR VARIAN UNITY 500 spectrometer, 499.83 MHz, solvent CD₃OD and CDCl₃, TMS as internal standard.

6, 6-*Ethylendioxy*-22-*hydroxy*-2 α , 3 α -*isopropylidenedioxy*-5 α -*cholest*-23-*yne*[26, 27-² H_6], **2**

A solution of $3-[^{2}H_{3}]$ methyl-but-1-yne- $[4, 4, 4-^{2}H_{3}]^{9}$, 11, (1.78 g) in dry THF (8 ml) was stirred and cooled to -78° C under an argon

Copyright © 2002 John Wiley & Sons, Ltd. J Label Compd Radiopharm 2003; 46: 231-242

atmosphere. *n*-BuLi in heptane (1.6 M; 12 ml) was added dropwise to this solution for 30 min. The solution was stirred for 1 h at -70° C, 30 min at -60° C and cooled again to -70° C. A solution of 6, 6-ethylendioxy-20-formyl-2 α , 3 α -isopropylidenedioxy-5 α -pregnane, 1.¹² (2.07 g) in dry THF (30 ml) was added dropwise at -70° C during 30 min. The resulting solution was stirred for 1 h and then warmed up to -10° C, before the solution was quenched by the addition of a saturated aqueous solution of ammonium chloride (20 ml). Two phases separated at room temperature and the water layer was extracted twice with EtOAc. The organic phase was dried with Na₂SO₄ and concentrated *in vacuo* to give 2.38 g (98.7%) **2**. This product was not further purified.

6, 6-*Ethylendioxy*-2 α , 3 α -*isopropylidenedioxy*-5 α -*cholest*-23-*yn*-22-*one*[26, 27-² H_6], **3**

A solution of **2** (2.38 g) in dry CH_2Cl_2 (15 ml) was added to a stirred suspension of pyridinium chlorochromate (PCC, 1.624 g) and natrium acetate (132 mg) in dry CH_2Cl_2 (15 ml). The mixture was stirred for 20 h at room temperature at the end of which the supernatant was removed and the residue washed twice with CH_2Cl_2 and as well as with diethylether. The supernatant and washings were filtered through florisil (26 g) and concentrated *in vacuo* to give 2.09 g of crude product which was purified by SiO₂ column chromatography. Elution with hexane/ EtOAc (8:2 v/v) gave 1.58 g (66.6%) of amorphous **3**. EI MS *m/z* (%) 518 (M⁺, 26), 503 (49), 307 (100), 254 (9), 239 (32), 99 (40), 87 (14), 73 (28).

6, 6-*Ethylendioxy* -22*R*-hydroxy-2 α , 3 α -isopropylidenedioxy-5 α -cholest-23-yne[26, 27-²H₆], **4**

For the stereoselective reduction of **3**, R-Alpine-Borane (R-B-3-pinanyl-9-borabicyclo[3.3.1]nonane) was used. 14.5 ml of R-Alpine-Borane solution (0.5 M in dry THF) was added dropwise under argon to a stirred solution of the 22-keto-23-acetylenic steroids (1.56 g) in dry THF (29 ml). This mixture was stirred under an argon atmosphere at room temperature for another 6 days. After evaporation of the solvent the crude residue was chromatographed on silica gel. Elution with hexane/ EtOAc (8:2 v/v) gave 1.45 g (92.4%) **4**, mp 173–176°C (CHCl₃) EI MS *m*/*z* (%) 520 (M⁺, 15), 505 (67), 417 (16), 359 (34), 309 (88), 254 (25), 239 (64), 99 (100), 81 (38), 73 (48).

(22R, 23Z)-6, 6-*Ethylenedioxy*-22-*hydroxy*-2 α , 3 α -*isopropylidenedioxy*-5 α -*cholest*-23-*ene* [26, 27-² H_6], **5**

1.17 ml of an NaBH₄ solution (201 mg NaBH₄ in 4.75 ml 95% EtOH and 0.25 ml 2N NaOH aq.) was added to a strongly stirred solution of nickel acetate (Ni(OAc)₂ · 4H₂O) (147.6 mg) in 95% EtOH (7.9 ml) under a strong current of nitrogen. After the addition of ethylenediamine (78.7 µml) in the next step compound **4** (1.21 g) dissolved in EtOH (8.34 ml) was added and the mixture was stirred under a hydrogen atmosphere for 20 h. Diethylether (15 ml) and Celite (1 g) were added before the mixture was filtered. The filtrate was concentrated *in vacuo*. The crude product was purified by SiO₂-chromatography. Elution with *n*-hexane/EtOAc (8:2 v/v) gave 1.055 g (86.9%) of **5**.

EI MS: *m*/*z* (%) 522 (M⁺, 4), 507 (25), 403 (28), 359 (100), 341 (19), 239 (26), 207 (45), 99 (62).

(22R, 23S, 24R)-2 α , 3 α -Isopropylidenedioxy-6, 6 -ethylendioxy-22 -hydroxy-23, 24epoxy-5 α -cholestane[26, 27-²H₆], **6**

Compound **5** (1.055 g) was dissolved in dry CH₂Cl₂ (50 ml). Anhydrous powdered Na₂HPO₄ (852 mg) was added. The mixture was stirred and cooled down to 5°C. Then *m*-chloroperbenzoic acid (MCPBA, 85%, 852 mg) was added. After stirring at 5°C for 6 h 0.5 N NaOH aq. (27 ml) was added to the reaction mixture. The organic layer was separated and the water layer extracted with CH₂Cl₂. The organic layer was dried with Na₂SO₄, concentrated *in vacuo* and chromatographed over SiO₂ with hexane/EtOAc (9:1–7 : 3 v/v) as the eluant to give 852.6 mg (78.4%) of **6** mp 154–157°C (from hexane). LC MS Rt 5.18 EI MS: *m/z* (%) 539 ([M + 1]⁺, 100), 522 (8), 499 (20), 460 (4). ¹H and ¹³C NMR data are displayed in Table 1.

(22R, 23R, 24S)-2 α , 3 α - *Isopropylidenedioxy*-6, 6- *ethylendioxy*-22, 23-*dihydroxy*-24-*methyl*-5 α -*cholestane*[26, 28-²H₆], **7**

To a stirred solution of the epoxy compound **6** (753 mg) in a mixture of dry cyclohexane (20 ml) and dry hexane (75 ml) under an argon atmosphere, cooled down to -78° C, two solutions were added, one of

Copyright © 2002 John Wiley & Sons, Ltd.

Me₃Al in *n*-heptane (2 N; 4.5 ml) and a second one of BuLi in *n*-hexane (1.6 M; 0.6 ml). The mixture was stirred for 1.5 h at -70° C and then it was slowly warmed up to room temperature. After 20 h the mixture was again cooled down to -40° C and the reaction was quenched by the addition of 1 N HCl (80 ml). The layers were separated and the water layer extracted with EtOAc. The collected organic layers were washed successively with NaHCO₃ aq. and brine and after this dried with Na₂ SO₄ and concentrated *in vacuo*. The residue was purified by chromatography over SiO₂ with *n*-hexane/EtOAc (3:2–1 : 1 v/v) as the eluant to give 370 mg (47.7%) of 7. mp 88–89°C (from EtOAc), [α]_D + 44.4 (c = 1,0; CH₃OH); EI-MS: *m*/*z* (%) 554 (M⁺, 26), 539 (70), 447 (27), 433 (29), 389 (62), 371 (24), 343 (100), 254 (26), 239 (46), 99 (71).

$[26, 28^{-2}H_6]$ Castasterone, 8

Compound 7 (340.8 mg) was dissolved in acetic acid/water (4:1; 20 ml) and then warmed up at 50°C for 1.5 h. After cooling to room temperature the solution was neutralized with Na₂CO₃ and extracted with CHCl₃. The CHCl₃ layer was dried with Na₂SO₄ and concentrated *in vacuo* to give [26, 28-²H₆]castasterone, **8**, (289 mg; 99.9%) mp 250–2°C (from methanol). GC MS as boranate Rt 10.38 518 (M⁺, 27), 399 (10), 358 (18), 287 (32), 161 (78), 85 (100). Separation by HPLC: Merck, LiChrospher 100 RP 18, 10 µm, 250 × 10 mm, MeCN : H₂O (9 : 1 v/v), 5 ml min⁻¹, 210 nm. Rt 22.7 min. ¹H and ¹³C NMR data are displayed in Table 1.

$[26, 28-^2H_6]$ Brassinolide, **9**

Peroxytrifluoroacetic acid was generated *in situ* by slow addition of H_2O_2 aq. (30%; 0.48 ml) to stirred trifluoroacetic anhydride (2.96 ml) at 0°C under nitrogen. The stirred mixture was allowed to react for 0.5 h. Then a solution of [26, 28-²H₆]castasterone (204.6 mg) in CH₂Cl₂ (25 ml) was added dropwise. The solution was continuously stirred for 2 h at room temperature. The mixture was diluted with CH₂Cl₂ (20 ml) and washed successively with water (10 ml), with saturated NaHCO₃ aq. (2 × 10 ml), with 10% aq. NaHSO₃ (2 × 10 ml) and with brine (10 ml). The CH₂Cl₂ extract was dried with Na₂SO₄ and concentrated *in vacuo* to give 146 mg of crude product. Then the water layer was extracted with ethyl acetate. The ethyl acetate was dried and evaporated off to

give 51.7 mg of crude product. Both crude products (146 mg, 51.7 mg) were purified by chromatography over SiO₂ with CHCl₃/CH₃OH (1:0–9 : 1 v/v) as the eluant to give firstly 12.7 mg (5.0%) of the not-required monotrifluoroacetic ester of [26, 28-²H₆]brassinolide (R_f 0.42 Silufol CHCl₃/CH₃OH 9 : 1 v/v) and 138.3 mg (65.37%) of a mixture of **9** and **10**. Separation by HPLC: Merck, LiChrospher 100 RP 18, 10 µm, 250 × 10 mm, MeCN : H₂O (9 : 1 v/v), 5 ml/min⁻¹, 210 nm gave at Rt 16.5 min. 15 mg (7.1%) the isomer [26, 28-²H₆]brassinolide (the B-homo-5a-oxa-6-lacton), **10**, and at Rt 18.3 min. 93 mg (43.96%) pure [26, 28-²H₆]brassinolide, **9**, mp 285–7°C (from CH₃OH), [α]_D + 46.4 (c = 1, 0; CH₃OH), GC MS as boranate Rt 11.70 min. 534 (M⁺, 1) 374 (13), 345 (11), 177 (63), 161 (46), 85 (100).

¹H and ¹³C NMR data are displayed in Table 1.

Acknowledgements

The authors are indebted to the Fonds der Chemischen Industrie for financial support, to Dr D. Lichtblau for the gift of the 6,6ethylendioxy-20-formyl- 2α , 3α -isopropylidenedioxy- 5α -pregnane and Gudrun Hahn for the HPLC separations of the [26, 28-²H₆] castasterone and [26, 28-²H₆]brassinolide. We are also indebted to Matthias Findeisen, Leipzig, for recording the deuterium decoupled HMBC NMR spectrum of castasterone.

References

- 1. Sakurai A, Yokota T, Clouse SD (eds). *Brassinosteroids: Steroidal Plant Hormones*. Springer: Tokyo, 1999.
- 2. Khripach VA, Zhabinskii VN, de Groot AE. *Brassinosteroids: A New Class of Plant Hormones.* Academic Press: New York, 1999.
- Adam G, Schmidt J, Schneider B. Brossinosteroids: In *Prog Chem Org Nat Prod*, Herz W, Falk H, Kirby GW, Moore RE, Tamm Ch (eds), vol. 78. Springer: Wien, New York, 1999; 1–46.
- 4. Schneider B. In *Progress In Botany*, Esser K, Lüttge U, Beyschlag W, Hellwig F (eds), vol. 63. Springer: Berlin, Heidelberg, 2002; 286–306.
- Marquardt V, Adam G. In *Chemistry of Plant Protection*. Ebing W (ed. in chief), vol. 7. Springer: Berlin, 1991; 103–139.
- 6. Kolbe A, Schneider B, Voigt B, Adam G. J Label Compd Radiopharm 1997; **41**: 131.

- 7. Takatsuto S, Ikekawa N. Chem Pharm Bull 1986; 34: 1415, 4045.
- 8. Seto H, Fujioka S, Koshino H, Yoshida S, Watanabe T, Takatsuto S. *Tetrahedron Lett* 1998; **39**: 7525.
- 9. Kolbe A, Fuchs P, Porzel A, Baumeister U, Kolbe A, Adam G. J Chem Soc Perkin Trans I, 2002; 2022.
- 10. Landor SR, Patel AN, Whiter PF, Graeves PM. J Chem Soc C 1966; 1223.
- 11. Crandall JK, Keyton DJ, Kohne J. J Org Chem 1968; 33: 3655.
- 12. Lichtblau D. Ph.D. Thesis, University of Halle, 1998.
- 13. Midland MM, Kwon YC. Tetrahedron Lett 1984; 25: 5981.
- 14. Aburatani M, Takeuchi T, Mori K. Agr Biol Chem 1985; 49: 3557.
- 15. Pfaltz A, Mattenberger A. Angew Chemie 1982; 94: 79.
- 16. Stoldt M, Porzel A, Adam G, Brandt W. Magn Reson Chem 1997; 35: 629.
- 17. Kalinowski H-O, Berger St, Braun S. ¹³C NMRSpektroskopie. Georg-Thieme-Verlag: Stuttgart, New York, 1984; 149.